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Objective:Evaluatepredictorsofvaginalcolonizationwithlactobacilliaftertreatmentforbacterialvaginosis(BV).Methods.Vaginal
ﬂuid specimens from women with BV underwent qPCR for Lactobacillus crispatus, L. jensenii,a n dL. iners pre- and posttreatment.
Results. Few women with BV were colonized with L. crispatus (4/44, 9%) or L. jensenii (1/44, 2%), though all had L. iners. One
month posttreatment 12/44 (27%) had L. crispatus, 12/44 (27%) L. jensenii, and 43/44 (98%) L. iners. Presence of L. jensenii
posttreatmentwasassociatedwithcure(RiskRatio(RR)1.67;95%CI1.09–2.56);L.crispatusshowedasimilartrend(RR1.41;95%
CI 0.89–2.24, P = 0.14). Receptive oral sex was associated with 2.2-log10 lower concentration of L. crispatus (95% CI −4.38, −.02),
and digital-vaginal sex with 2.6-log10 lower concentration (95% CI −4.87, −.33). Conclusion. One month after BV treatment, few
women established colonization with L. crispatus or L. jensenii. Few behaviors were associated with colonization.
1.Introduction
Bacterialvaginosis(BV)isthemostcommoncauseofvaginal
dischargeinreproductiveagewomen[1],ispresentinappro-
ximately 29% of women in the United States [2], and is
characterized by vaginal colonization with anaerobic bacter-
ialspeciesalongwithlossoflactobacilli.Theclinicalsequelae
of BV are signiﬁcant—a nearly two-fold-increased risk of
HIV-1 acquisition [3, 4], preterm delivery [5, 6], and pelvic
inﬂammatory disease (PID) [7]—and aﬀect millions of
women worldwide each year, making BV a signiﬁcant health
problem. Treatment with antibiotics has a cure rate of 50–
80% [8, 9] but recurrence within 1 to 3 months is common
(30–52%) [10–12].
Hydrogen peroxide (H2O2-)producingspeciesofvaginal
lactobacilliareassociatedwithdecreasedratesofBV[13,14],
and better reproductive health outcomes [15, 16]c o m p a r e d
tonon-H2O2-producingspecies.Lactobacilluscrispatusisthe
most common vaginal H2O2-producing Lactobacillus species
[17, 18]. L. jensenii is another frequently isolated H2O2-
producing species [18, 19]. Some hypothesize that the recur-
rence rate of BV is high because these protective lactobacilli
do not recolonize the vagina after antibiotic treatment aimed
at eradicating BV-associated anaerobes, and so leave an eco-
logic void that is quickly reﬁlled by opportunistic organisms.
In one study, only 40% of women were recolonized with
any H2O2-producing species of lactobacilli 30 days after oral
metronidazole treatment and 57% were recolonized 30 days
after vaginal clindamycin [20]. Most women are colonized
with a single dominant species of Lactobacillus [21], but it
is unclear if this is because there is competition between
species for the vaginal niche. A majority of women studied
in the US are colonized with Lactobacillus iners [22, 23], a
fastidious species that does not commonly produce H2O22 Infectious Diseases in Obstetrics and Gynecology
and that has been associated with increased risk of abnormal
vaginal microbiota in pregnant women [24]. Little is known
about the eﬀect of L. iners on a woman’s ability to colonize
with beneﬁcial H2O2-producing species.
Presence of H2O2-producing lactobacilli [14, 25, 26],
speciﬁcally L. crispatus [24], has been associated with
decreased risk of abnormal vaginal microbiota and BV; thus,
recolonization with these species after treatment for BV is
likely an important marker of vaginal health. We under-
took this nested cohort study to evaluate the eﬀect of sex-
ual behavior on vaginal recolonization with two hydrogen
peroxide producing Lactobacillus species, L. crispatus and L.
jensenii, one month after treatment for BV.
2. Methods
2.1. Study Population and Design. We conducted an anal-
ysis of women diagnosed with and treated for BV while
enrolled in an observational cohort study in Seattle, WA.
As previously described, participants were recruited through
advertisements, media, and community referral, and had to
be ≥16 years old and report having had sex with at least
one woman in the previous year, a group with relatively
high BV prevalence [27]. Study visits were scheduled every
three months for a year, with additional visits for vaginal
symptoms and/or 4 weeks after treatment for BV. At each
visit, participants completed a computer-assisted self-inter-
view (CASI) thatcollectedinformation aboutdemographics,
sexual practices, medical, and reproductive history. The
study was approved by the University of Washington Institu-
tional Review Board and all participants provided informed
consent at enrollment. Participants underwent pelvic exami-
nationwithcollectionofvaginalswabsforsalinemicroscopy,
Gram stain, and bacterial culture. A separate foam swab was
collected by rolling along the vaginal wall and was then fro-
zen at −80◦C for use in molecular assays. Women diagnosed
with BV by Amsel’s clinical criteria [28]w e r et r e a t e dw i t h
vaginal metronidazole gel, 37.5mg nightly for 5 nights, and
assessed at a followup visit after 4 weeks. Vaginal ﬂuid Gram
stains were scored using the criteria outlined by Nugent
et al. [29], however, treatment success was deﬁned solely as
absence of BV by Amsel’s criteria.
We included all participants who were diagnosed with
BV during the study and whose followup visits occurred 3 to
8 weeks after treatment. Only the ﬁrst BV-positive visit was
included for participants who were diagnosed with BV more
than once. The study was conducted between October 2003
and December 2006, but between 3/2/2004 and 12/8/2005,
only women with vaginal pH > 4.5 at the followup visit had
samples taken follow-up (due to limitations in study fund-
ing). Because of this diﬀerential assessment and the resulting
potential bias, all women whose followup visits fell within
this time period were excluded. Participants whose samples
didnothaveenoughmaterialtocompleteallPCRassayswere
also excluded.
2.2. Molecular Assays. Frozen vaginal swabs from the BV-
positive visit and a followup visit within 3–8 weeks were pro-
cessed as previously described [30]. All extracted DNA was
testedinaquantitativePCRassayusingprimerstargetingthe
human18SrRNAgenetovalidatethatsuccessfulDNAextra-
ction occurred. An internal ampliﬁcation control PCR using
exogenousDNAfromajellyﬁshgenewasusedtotestforpre-
sence of PCR inhibitors [31].
Vaginal ﬂuid samples were then subjected to taxon-
directed 16S rRNA gene quantitative PCR assays for the
detectionandquantiﬁcationofL.crispatus,L.jensenii,andL.
iners [30, 32]. Each assay has previously been validated and
provensensitive(toalevelof1–10DNAcopies/reaction)and
speciﬁc (does not detect other bacteria at a concentration of
106 copies/reaction). The assays use a TaqMan format, and
are run on an ABI 7500 Thermocycler (Applied Biosystems,
Foster City, CA) or Eppendorf Mastercycler ep Realplex ther-
mal cycler (Eppendorf, Westbury, NY).
2.3. Statistical Analysis. The primary outcome of interest
was presence or absence of L. crispatus or L. jensenii after
treatment for BV. In secondary analyses, we assessed the rela-
tionship between sexual behaviors and quantities of bacteria,
expressed as 16S rDNA gene copies/vaginal swab and log
transformed. Univariate log binomial regression was used to
assess the relationship between presence or absence of either
L. crispatus or L. jensenii and (a) diﬀerent behaviors, and (b)
presenceandquantityof L.iners.Univariatelinearregression
was used to assess the relationship between sexual behaviors
and quantity of L. crispatus or L. jensenii in the subset of
women who were colonized. Given the relatively small num-
ber of women, we did not perform multivariate analyses.
3. Results
A total of 336 women were enrolled in the observational
cohort. Of these, 136 (40%) were diagnosed with BV during
the study: 96 at enrollment, and 40 at a routine study visit or
a nonscheduled visit with symptomatic BV. Eleven women
never returned for followup, 58 women had followup visits
that fell during the period of exclusion, and 23 did not have
adequate sample remaining for all of the assays and were
excluded, leaving 44 women available for this analysis.
3.1. Baseline Characteristics. The 44 women had a mean age
of 25 ± 3 years and were primarily white (35/44; 80%). Half
of the visits occurred during the proliferative phase of the
menstrual cycle, and half in the luteal phase. The majority of
womenhadonlyfemalepartners(31/44;70%),whilesmaller
percentages had male only (4/44; 9%), partners of both
genders (4/44; 9%) or no sexual partner in the last 3 months
(5/44; 11%). All women had BV by Amsel’s criteria, and 98%
(43/44) also had BV by Nugent’s score, which was signiﬁ-
cantly diﬀerent than women excluded from this substudy, of
whomonly85% (78/92) had BV byNugent’s score(P = .02).
Thiswastheonlycharacteristicthatdiﬀeredbetweenwomen
in the substudy and those that were excluded. Women in the
substudy were as likely to complete antibiotic treatment for
BVaswomeninthelargercohort(89%versus90%;P = .95).
At diagnosis, 29/44 (66%) women reported having had
receptive oral-vaginal contact in the previous 90 days. Slight-
ly more reported digital-vaginal sex (82%), while fewerInfectious Diseases in Obstetrics and Gynecology 3
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Figure 1: Change in concentrations of three diﬀerent species of lactobacilli, as measured by species-speciﬁc quantitative PCR, 4 weeks
after treatment for bacterial vaginosis with vaginal metronidazole. Each line represents an individual patient and her concentration of each
bacterium before and after treatment. The dotted line represents the lower limit of detection of the qPCR assay.
reported toy-vaginal sex (36%) during that same time. Only
8 (18%) women reported sexual contact with a male partner
in the 3 months prior to BV diagnosis, 7 of whom reported
having penile-vaginal sex during that time. All 44 women
were colonized with L. iners at BV diagnosis, while few were
colonized with L. crispatus (4/44, 9%) or L. jensenii (1/44,
2%).
3.2. Posttreatment Characteristics. Nearly all women (43/44;
98%) were colonized with L. iners after treatment. Only
12/44 (27%) were colonized with L. crispatus and 12/44
(27%) with L. jensenii. Of those, six women were colonized
with both species, and six each with only one of the two
species. Posttreatment, 18 women (41%) still met Amsel’s
criteria for BV and were considered to have failed treatment,
all of whom also had a Nugent score ≥7. Among these
women, only 3 (16.7%) were colonized with L. crispatus and
2 (11.1%) with L. jensenii. Of the 26 women who achieved
cure, a slightly higher percentage (but still a minority) were
colonizedwithL.crispatus(9/26;35%)andL.jensenii(10/26;
38%). Presence of L. crispatus at diagnosis or followup
trended towards association with cure (Risk Ratio 1.41; 95%
CI .89, 2.24; P = .14), but this was not statistically signiﬁ-
cant. Women colonized with L. jensenii after treatment had
signiﬁcantly higher rates of treatment success (RR 1.67; 95%
CI 1.09, 2.56; P = .02).
Of the four women colonized with L. crispatus at BV
diagnosis, one achieved cure and had higher concentrations
after treatment, while 3 failed treatment, and had lower
(n = 2) or undetectable (n = 1) concentrations. The one
woman colonized with L. jensenii at BV diagnosis no long-
er had detectable colonization after treatment, and also
failed treatment (Figure 1). Among colonized women, mean
Log10 concentration of L. crispatus after treatment was 6.1 ±
1.9 gene copies/mL and for L. jensenii was 6.0 ± .7g e n e
copies/mL. All 44 women were colonized with high quant-
ities of L. iners at the BV diagnosis visit (mean Log10 copies
6.5±.9), and the quantity did not change signiﬁcantly at the
followup visit (mean Log10 copies 6.7 ±1.1; P = .40).
Between the visit at which BV was diagnosed and
treatment provided, and subsequent followup (median 33
days,IQR28–37),21/44women(48%)reportedoral-vaginal
sex, 26 (59%) digital-vaginal sex, 8 (18%) penile-vaginal sex,
and 9 (20%) toy-vaginal sex. Among all 44 women, no inter-
imsexualbehaviorswereassociatedwithpresenceorabsence
ofeitherL.jenseniiorL.crispatusatthefollowupvisitorwith
treatment failure (Table 1). Among women who were col-
onized with L. jensenii or L. crispatus at the followup visit,
we examined whether behaviors reported in the interim
period between treatment and followup at 32 days were
associated with quantity of bacteria detected at the followup
visit (Table 2). In the subset of 12 women establishing
colonization by followup, report of digital-vaginal sex was
signiﬁcantly associated with 2.6-Log10 lower concentrations
of L. crispatus (95% CI −4.87, −.33). Report of receptive oral
sex was associated with 2.2-Log10 lower concentrations of
L. crispatus (95% CI −4.38, −.02). No behaviors were asso-
ciated with quantity of L. jensenii detected at that visit.
4. Discussion
In this cohort of women reporting sex with women, rates
of vaginal colonization with two species of commensal
H2O2-producing lactobacilli four weeks after treatment4 Infectious Diseases in Obstetrics and Gynecology
Table 1: Univariate association between reported sexual behaviors during treatment and followup and presence of L. crispatus or L. jensenii
at the posttreatment visit.
Presence of L. crispatus
(n = 44)
Presence of L. jensenii
(n = 44)
BV diagnosis by Amsel’s at followup
(n = 18)
Sexual behavior during
followup period N Prevalence ratio Prevalence ratio Prevalence ratio
Number of partners 12 Reference Reference Reference
0
1 26 1.62 (.39, 6.65) 1.12 (.34, 3.46) 1.1 (.50, 2.44)
2+ 6 3.0 (.67, 13.4) 1.33 (.30, 5.96) .4 (.06, 2.70)
Oral vaginal sex 21 2.19 (.77, 6.22) 1.53 (.57, 4.1) 1.10 (.54, 2.23)
Digital-vaginal sex 26 2.08 (.65, 6.63) 2.08 (.65, 6.63) .87 (.43, 1.76)
Toy-vaginal sex 9 1.30 (.44, 3.82) .78 (.21, 2.94) 1.11 (.48, 2.56)
Penile-vaginal sex 8 .9 (.24, 3.34) .9 (.24, 3.34) .9 (.34, 2.38)
Use of vaginal lubricant 11 2.42 (.66, 8.93) .30 (.04, 2.21) .73 (.30, 1.78)
Table 2: Association between reported sexual behaviors during treatment and followup and quantity of L. crispatus or L. jensenii in women
who were colonized at the posttreatment visit.
Sexual behavior during
followup period
L. crispatus L. jensenii
N Log10 diﬀerence in 16S rRNA copies/mL N Log10 diﬀerence in 16S rRNA gene copies/mL
Number of partners
0 2 Reference 3 Reference
17 −1.66 (−4.87, 1.55) 7 −.03 (−1.21, 1.16)
2+ 3 −3.13 (−6.52, .25) 2 −.16 (−1.73, 1.40)
Oral vaginal sex 8 −2.20 (−4.38, −.02) 7 −.11 (−1.05, .83)
Digital-vaginal sex 9 −2.60 (−4.87, −.33) 9 −.06 (−1.13, 1.02)
Toy-vaginal sex 3 −1.65 (−4.32, 1.03) 2 −.15 (−1.39, 1.09)
Penile-vaginal sex 2 .69 (−2.67, 4.04) 2 −.14 (−1.39, 1.10)
Use of vaginal lubricant 4∗ −2.92 (−6.09, .24) 1∗ −.53 (−2.07, 1.0)
∗Missing data for 5 women.
for bacterial vaginosis were low. Though colonization was
infrequent, women who were able to establish colonization
achieved high concentrations of each of these bacteria.
For clinicians and aﬀected women, the high rate of BV
recurrence after antibiotic treatment is exceedingly frustrat-
ing [10–12]. Several groups have evaluated whether adding
probiotic compounds containing lactobacilli to treatment
improves outcomes, but results have been mixed [33–36].
In a study of healthy women treated with vaginal probio-
tic capsules containing L. crispatus, participants who report-
ed penile-vaginal sex between treatment and followup were
less likely to establish colonization with the probiotic strain
[37]. We hypothesized that sexual activity in the month
after treatment may inhibit vaginal colonization with ben-
eﬁcial lactobacilli, possibly through reinoculation with BV-
associated bacteria from vulvar or rectal reservoirs, which
might increase risk for BV recurrence.
In the parent study of nearly 350 women from which this
nested case control study was derived, we demonstrated that
women cured of BV had higher rates of colonization by L.
crispatus after treatment (42%) than women with persistent
BV (26%; P = .0003); data on L. jensenii were not available
[30].Adiﬀerentstudyobtainedvaginalswabsforcultureand
found that by 4 weeks after treatment with vaginal metro-
nidazole 59% of women were colonized with hydrogen per-
oxide producing lactobacilli [20]. Other studies used Nugent
score to characterize shifts of the vaginal bacteria, and
reported that as many as 66% of treated women had at
least some lactobacilli at 21–30 days after treatment [38],
though H2O2 production was not measured. Our group pre-
viously measured posttreatment quantity of L. crispatus in a
cohort of pregnant women using PCR and found that only
9/53 (17%) of women had detectable levels 4–6 weeks after
treatment [39].
Few studies have evaluated behavioral predictors of
colonization with lactobacilli. In women with BV, those
who report more sexual partners are less likely to be col-
onizedwithH2O2-producinglactobacilli[40].Inourcohort,
women colonized with L. crispatus who reported digital-
vaginal and/or oral-vaginal sex had lower quantities of this
bacterium. Although it did not reach statistical signiﬁcance,
we saw a paradoxical opposite trend in the risk related to
these behaviors for vaginal colonization with L. crispatus or
L. jensenii, suggesting that women with more partners, orInfectious Diseases in Obstetrics and Gynecology 5
reporting more frequent oral-vaginal or digital-vaginal sex,
were more likely to be colonized. One possible explanation
is that women colonized by L. crispatus and L. jensenii more
likely achieved cure of BV, thus reducing the likelihood of
vaginal symptoms that might deter them from engaging in
sex. This observation highlights the diﬃculty in studying
the complex relationships between sexual behaviors and the
dynamic nature of vaginal microbiology—temporal associa-
tions are diﬃcult to ascertain unless both outcomes are
measured frequently (ideally, daily).
The main limitation of this study is the small sample size,
which reduced our power to detect potential associations
betweenbehaviorsandcolonizationwithspeciﬁclactobacilli.
A signiﬁcant number of participants with BV did not have a
posttreatment sample, which limited our ability to examine
the entire study group. Participants selected for this substudy
were similar to the larger cohort except for having higher
Nugent scores at diagnosis, which may partially explain their
high rate of treatment failure. This cohort is composed pri-
marily of women who have sex exclusively with women, and
our results may diﬀer from those obtained in a cohort of
primarily heterosexual women. However, this allowed us to
study the eﬀect of several diﬀerent types of sexual behav-
ior on the vaginal microbiota. The population had well-cha-
racterizedinformationaboutsexualactivityduringthetreat-
ment period, and a very high rate of followup (92%). Our
quantitative PCR analysis allowed detection of small quant-
itiesofbacteriaandanalysisofchangesinquantityofbacteria
after treatment with respect to sexual behaviors.
5. Conclusions
Vaginal colonization with H2O2-producing lactobacilli 4
weeks after treatment for BV was uncommon, suggesting
that there is a window of vulnerability during which women
may be more susceptible to reinfection or recurrence. While
no sexual behaviors were found to impact presence of col-
onization, quantity of L. crispatus was decreased in women
reporting digital-vaginal and oral-vaginal contact. Quantity
of L. jensenii was not aﬀected by any reported sexual behav-
iors. This suggests that some species of commensal lacto-
bacilli may be more sensitive to the eﬀect of sexual activity
on the vaginal environment.
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